On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 3.25% from the last session, before settling in for the closing price of $8.01. Price fluctuations for RXRX have ranged from $5.60 to $15.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 132.77% annually for the last half of the decade. Company’s average yearly earnings per share was noted 2.32% at the time writing. With a float of $302.39 million, this company’s outstanding shares have now reached $388.78 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 22.22%, while institutional ownership is 58.14%. The most recent insider transaction that took place on Dec 04 ’24, was worth 143,200. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $7.16, taking the stock ownership to the 736,633 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chief Executive Officer sold 20,000 for $7.12, making the entire transaction worth $142,400. This insider now owns 736,633 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 2.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 59.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 19.79 million. That was better than the volume of 6.38 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.05%. Additionally, its Average True Range was 0.68.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 67.59%, which indicates a significant increase from 67.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.47% in the past 14 days, which was higher than the 81.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.64, while its 200-day Moving Average is $8.05. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $9.16. Second resistance stands at $10.04. The third major resistance level sits at $10.54. If the price goes on to break the first support level at $7.78, it is likely to go to the next support level at $7.28. The third support level lies at $6.40 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 286,641K shares outstanding in the company with a market cap of 3.91 billion. Presently, the company’s annual sales total 44,580 K according to its annual income of -328,070 K. Last quarter, the company’s sales amounted to 26,080 K and its income totaled -95,840 K.
